A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

3,037

Participants

Timeline

Start Date

April 20, 2015

Primary Completion Date

October 14, 2016

Study Completion Date

October 14, 2016

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Acetylsalicylic acid

ASA 100 mg enteric-coated tablet once daily orally.

DRUG

Rivaroxaban

Rivaroxaban 2.5 mg tablet twice daily orally.

DRUG

Clopidogrel

Clopidogrel 75 mg once daily orally.

DRUG

Ticagrelor

Ticagrelor 90 mg twice daily orally.

Trial Locations (259)

Unknown

Alexander City

Banning

Sylmar

Aurora

Littleton

Jupiter

Miami

Orlando

Pensacola

Tampa

Athens

Cumming

Macon

Tucker

Boise

Coeur d'Alene

Jerseyville

Indianapolis

Munster

Bay City

Kalamazoo

Lansing

Mount Clemens

Ypsilanti

Minneapolis

Columbia

St Louis

Kalispell

Stony Brook

Rocky Mount

Sanford

Cincinnati

Zanesville

Bartlesville

Tulsa

Abington

Langhorne

Philadelphia

Sayre

York

Rapid City

Oak Ridge

Amarillo

Fort Sam Houston

Houston

Odessa

San Antonio

Danville

Puyallup

Buenos Aires

Caba

Ciudad de Buenos Aires

Cordooba

Corrientes

Córdoba

La Plata

Mar del Plata

Resistencia

Rosario

Salta

San Martín

Santa Fe

Brisbane

Cairns

Chermside

Elizabeth Vale

Herston

Hobart

Launceston

Liverpool

Murdoch

Nambour

New Lambton Heights

Antwerp

Bonheiden

Brasschaat

Bruges

Edegem

Genk

Ghent

Huy

Liège

Mol

Roeselare

Ronse

Turnhout

Belo Horizonte

Blumenau

Campina Grande do Sul

Campinas

Curitiba

Marília

Passo Fundo

Porto Alegre

Recife

Salvador

São José do Rio Preto

São Paulo

Tatuí

Uberlândia

Votuporanga

Blagoevgrad

Burgas

Haskovo

Lovech

Pazardzhik

Pleven

Rousse

Sandanski

Sofia

Varna

Edmonton

New West Minister

Victoria

Greater Sudbury

London

Newmarket

Toronto

Montreal

Saint-Charles-Borromée

Sherbrooke

Québec

Brno

Kolin Iii.

Ostrava

Plzen-Bory

Prague

Třebíč

Znojmo

Herlev

Køge

Silkeborg

Besançon

Chambray-lès-Tours

Jossigny

Le Coudray

Lyon

Montauban

Nantes

Périgueux

Balatonfüred

Budapest

Debrecen

Győr

Gyula

Kaposvár

Kecskemét

Nyíregyháza

Székesfehérvár

Szolnok

Gifu

Kagawa

Kitakyushu

Kobe

Kumamoto

Matsue

Nagano

Osaka

Sayama-Shi

Tokyo

Uwajima-Shi

Yokohama

Yonago

Yotsui 2-8-1

's-Hertogenbosch

Amersfoort

Amsterdam

Blaricum

Den Helder

Gouda

Groningen

Hoofddorp

Hoogeveen

Nijmegen

Rotterdam

Schiedam

The Hague

Bielsko-Biala

Bytom

Chrzanów

Dąbrowa Górnicza

Gdynia

Grodzisk Mazowiecki

Inowrocław

Kędzierzyn-Koźle

Kielce

Koszalin

Krakow

Lodz

Nowy Targ

Nysa

Oświęcim

Polanica-Zdrój

Puławy

Tychy

Warsaw

Włocławek

Barnaul

Chita

Ivanovo

Kaliningrad

Kemerovo

Krasnodar

Krasnoyarsk

Moscow

Nizhny Novgorod

Orenburg

Penza

Perm

Rostov-on-Don

Saint Petersburg

Samara

Syktyvkar

Tyumen

Yekaterinburg

Gwangju

Incheon

Seongnam

Seoul

Suwon

A Coruña

Almería

Ávila

Barcelona

Madrid

Málaga

Murcia

Sant Boi de Llobregat

Tarragona

Falun

Jönköping

Linköping

Lund

Örebro

Östersund

Stockholm

Sundsvall

Uppsala

Adana

Ankara

Aydin

Bursa

Diyarbakır

Eskişehir

Istanbul

Kahramanmaraş

Kocaeli

Konya

Sivas

Cherkasy

Dnipropetrovsk

Kharkiv

Kyiv

Lutsk

Lviv

Odesa

Ternopil

Zaporizhzhia

Zhytomyr

Sponsors
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Duke Clinical Research Institute

OTHER

collaborator

Harvard Medical School (HMS and HSDM)

OTHER

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02293395 - A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome | Biotech Hunter | Biotech Hunter